The impact of Bruton’s tyrosine kinase inhibitor treatment on COVID-19 outcomes in Chinese patients with chronic lymphocytic leukemia

The impact of Bruton’s tyrosine kinase inhibitor treatment on COVID-19 outcomes in Chinese patients with chronic lymphocytic leukemia

BackgroundImpact of B-cell depletion following treatment with Bruton tyrosine kinase-inhibitors (BTKi) on the outcome of SARS-CoV-2 infection in chronic lymphocytic leukemia (CLL) patients remain controversial. We investigated the impact of BTKi on susceptibility and the severity of COVID-19 in Chin...

Full description

Bibliographic Details
Main Authors: Shenmiao Yang, Rong Wei, Hongxia Shi, Yazhe Wang, Yueyun Lai, Xiaosu Zhao, Jin Lu, Norbert Schmitz
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-05-01
Series:Frontiers in Oncology
Subjects:
BTK inhibitors
COVID-19
chronic lymphocytic leukemia
SARS-CoV-2
anti CLL treatment
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1396913/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2024.1396913/full

Similar Items